Bełtowski and Jamroz-Wiśniewska in the vascular wall and myocardium, and is activated not only by EGF itself but also by many vasoconstrictors such as angiotensin II, endothelin-1 and norepinephrine. Enhanced EGFR signaling has been demonstrated in experimental models of arterial hypertension and myocardial hypertrophy. Therefore, targeting EGFR is a promising therapeutic strategy for cardiovascular diseases.
The aim of this article is to provide general overview of EGFR signaling and to discuss role of this receptor in the regulation of vascular tone and renal sodium handling -two major determinants of blood pressure -under physiological conditions and in arterial hypertension. Moreover, potential therapeutic implications are also addressed. Role of EGFR in other aspects of cardiovascular pathology such as congenital heart defects, atherogenesis, myocardial hypertrophy, ischemia-reperfusion injury and hypertension-induced renal damage has been recently described in excellent reviews (1) (2) (3) .
EGFR AND ITS LIGANDS: AN OVERVIEW

Family of ErbB receptors
EGF receptor was identified as a plasma membrane-bound protein tyrosine kinase in 1980 (4) . In 1984, Downward et al demonstrated that v-ErbB oncogene of avian erythroblastosis virus encodes a truncated form of EGFR (5) . Currently, EGF receptor is classified as a first member of ErbB family of receptor tyrosine kinases, and thus is also referred to as ErbB1 or HER1 (from Human Epidermal Growth Factor Receptor 1). In 1984, Schechter et al identified neu oncogene in ethylnitrosourea-induced neuroblastoma, and demonstrated its sequence similarity with v-ErbB (6) ; this oncogene encodes a cell surface protein having a molecular weight of 185 kD (7) .
The respective protein encoded by a cellular protooncogene was termed p185 her2/neu (now referred to as HER2 or ErbB2); oncogenic protein differs from p185 her2/neu by a single point mutation (valine to glutamic acid substitution at residue 664) (8) . Two other members of ErbB family -ErbB3 and ErbB4 -were identified later. Overexpression or oncogenic mutations of ErbB receptors (in particular ErbB1 and ErbB2) are observed in many human tumors. Currently known members of the ErbB family and their ligands are listed in Table 1 . All ErbB receptors are single-chain transmembrane proteins with its N-terminus outside and C-terminus inside the cell (Fig. 1) . Upon ligand binding, the receptor dimerizes with the same (homodimerization) or other member of ErbB family (heterodimerization), and intracellular tyrosine kinase (TK) domain is activated to phosphorylate the receptor itself as well as various signaling proteins (see below). No ligand was identified for ErbB2, and recent studies indicate that conformation of this receptor makes it unable to bind any ligand. Indeed, the conformation of extracellular domain of unliganded ErbB2 resembles the conformation of ligand-bound form of other members. Therefore, ErbB2 is able to heterodimerize with other ErbB receptors, and is actually a preferred dimerization partner. When ErB2 forms dimer with other ErbB receptor, it may be phosphorylated by tyrosine kinase domain of its dimeric partner and vice versa, TK domain of ErbB2 may phosphorylate the intracellular domain of its partner. Consequently, both components of the dimer are involved in signal transduction, although precise signaling pathways triggered by both partners are not necessarily identical (9) .
Apart from ErbB2, ErbB3 is also "atypical" in that it lacks the TK domain. Nevertheless, ligand-bound ErbB3 may noncovalently activate its heterodimeric partner as well as may be 
ErbB4
ErbB4 NRG-1, NRG-2, NRG-3, NRG-4 HB-EGF, EPR, BTC TGF-α -transforming growth factor-α, HB-EGF -heparin-binding epidermal growth factor, AR -amphiregulin, EPR -epiregulin, BTC -betacellulin, NRG -neuregulins EGF receptor and hypertension phosphorylated by its partner to perform signal transduction. Despite "atypical" characteristics of its components, ErbB2/ ErbB3 heterodimer is a most potent mitogenic combination among all known ErbB dimmers. ErbB family is an evolutionary ancient signaling system which, however, was becoming more and more complicated during the evolution. For example, in Caenorhabditis elegans only one receptor homologous to mammalian ErbB is known (LET-23), and this receptor has only one ligand (LIN-3). In a fruitfly, Drosophila melanogaster, there is one ErbB-like receptor but it may be bound by 5 ligands. Interestingly, one of these ligands is a receptor antagonist, whereas no endogenous antagonists of ErbB receptors were found in mammals.
ErbB receptors and their ligands are involved in the regulation of cell growth, proliferation and survival. Although this signaling system plays an important role during the development and in rapidly proliferating (e.g. epithelial) cells of the adult organism, it was studied mainly in the context of malignancies. Three types of abnormalities within this system may contribute to uncontrolled cell proliferation: (i) oncogenic mutations within the ErbB genes, which cause ligand-independent receptor overactivity, (ii) overexpression of ErbB receptors, and (iii) overexpression of their ligands. Abnormalities of the ErbB system have been observed in many cases of breast, gastric, ovarian, urinary bladder, pancreatic and other cancers (10) .
EGF receptor: ligand binding and signaling mechanisms
Human EGFR consists of 1186 aminoacids ( Fig. 1) and is a 170 kD protein originating from a 1210-residue precursor (9) . Its extracellular domain consists of 4 subdomains which, counting from the N-terminus, are referred to as I, II, III and IV, or L1, CR1, L2 and CR2, respectively. Domains L1 and L2 are involved in ligand binding. Upon interaction with ligand, conformation of the receptor changes such that domain CR1 is exposed to bind CR1 domain of a dimeric partner. With the exception of ErbB2, other ErbB homo-and heterodimers are activated in a "2+2" manner, i.e. each of two receptors in its monomeric form binds one ligand, and then these two ligandbound monomers dimerize to form an active complex.
Transmembrane domain of EGFR consists of 23 hydrophobic aminoacids. The role of juxtamembrane domain is unknown, however, it is suggested that this region is involved in sorting of newly formed receptors to the basolateral membranes of epithelial cells, as well as in internalization/downregulation of receptors upon ligand binding. The next tyrosine kinase domain ( Fig. 1) phosphorylates the receptor itself (autophosphorylation) and intracellular signaling proteins. Finally, C-terminal domain contains 5 autophosphorylation tyrosine residues (Tyr  992 , Tyr  1068 , Tyr  1086 , Tyr  1148 and Tyr   1173 ), which bind various adaptor proteins containing Src homology-2 (SH2) or phosphotyrosine-binding (PTB) domains (Table 2) . Activated EGF receptor triggers many signaling pathways including (i) extracellular signal-regulated kinases (ERKs), (ii) phosphoinositide 3-kinase (PI3-K) -protein kinase B/Akt, and (iii) phospholipase Cγ.
Extracellular signal-regulated kinases-1 and -2 (ERK1/2) are serine/threonine kinases belonging to a large family of mitogen-activated protein kinases (MAPKs), and due to their molecular weights are also referred to as p44 MAPK and p42 MAPK, respectively. Most mitogenic and growth-promoting effects of EGFR are mediated by ERKs. ERKs are activated through the phosphorylation cascade including Ras protein, Raf kinase, and two specific mitogen activated protein kinase Bełtowski and Jamroz-Wiśniewska kinases-1 and -2 (MAPKKs or MAP2Ks), also referred to as MAPK/ERK kinase-1 and -2 (MEK1 and MEK2), which finally phosphorylate ERK1 and ERK2, respectively (Fig. 2) . Phosphorylated EGFR recruits Growth hormone receptorbinding-2 (Grb2) adaptor protein either directly or through Src homology-containing protein (Shc); in the latter case, Shc first binds to EGFR and then recruits Grb2. Under resting conditions, Grb2 is constitutively bound to "Son of sevenless" (Sos) guanine nucleotide exchange factor. Relocation of Grb2-Sos complex to the plasma membrane allows the interaction of Sos with membrane-bound Ras protein; consequently, Sos catalyzes the exchange of GDP for GTP thus converting Ras from its inactive to active form. GTP-bound Ras activates Raf kinase, which phosphorylates MEK1 and MEK2 (Fig.2) . To become active, Ras proteins have to be farnesylated, e.g. bound to the farnesyl group (isoprenoid group produced from mevalonate) by protein farnesyltransferases. Ras possesses an intrinsic GTPase activity; this activity is enhanced by GAP (GTPase-activating proteins). Hydrolysis of Ras-bound GTP to GDP inactivates Ras and terminates Raf-MEK-ERK signaling.
The second pathway triggered by EGFR is PI3-K. PI3-K phosphorylates phosphoinositides at 3-position of inositol ring thus converting phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-triphosphate, or phosphatidylinositol 4-phosphate to phosphatidylinositol 3,4-bisphosphate. These phosphoinositides activate phosphoinositide-dependent protein kinases-1 and -2 (PDK-1 and PDK-2), which then phosphorylate and activate protein kinase B (Akt). PI3-K-PKB/Akt pathway inhibits apoptosis and plays an important role in the regulation of cell survival. One of the PKB substrates is mammalian target of rapamycin (mTOR), which activates ribosomal p70S6 kinase and thus stimulates protein synthesis. EGFR also activates several phospholipases and enhances breakdown of membrane phospholipids. Phospholipase Cγ (PLCγ) is phosphorylated by TK domain of EGFR and hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate to diacylglycerol (DAG), which activates protein kinase C EGF receptor and hypertension (PKC) 
ErbB receptor ligands
All ErbB receptor ligands are synthesized as plasma membrane-bound precursors from which mature soluble growth factors are released. Interestingly, both soluble and membranebound ligands can bind to their receptors. Membrane-bound ligands bind only receptors on adjacent cells (juxtacrine signaling), whereas soluble ligands signal in a paracrine/autocrine manner. All ligands contain a characteristic EGF-like domain consisting of 40-50 aminoacids. This domain contains 6 spatially conserved cysteine residues arranged in a sequence CX7CX4-5CX10-13CXCX8C (C-cysteine, X-any aminoacid), and linked by three disulfide bonds in a pattern C1-C3, C2-C4 and C5-C6. Ligands of ErbB receptors may be classified into three groups (Table 1) : (i) epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α) and amphiregulin (AR), which bind only EGFR, (ii) heparin-binding epidermal growth factor (HB-EGF), epiregulin (EPR) and betacellulin (BTC), which bind EGFR and ErbB4, and (iii) neuregulins (NRG), which bind either ErbB3 and ErbB4 (NRG-1, NRG-2) or only ErbB4 (NRG-3 and NRG-4). EGF is an archetypical growth factor which was first isolated from mice submandibular gland and identified because of its effect on tooth eruption and eyelid opening in newborn animals (12) . Its human equivalent was initially called β-urogastrone, because was isolated from urine and demonstrated to inhibit gastric acid secretion (13) . In humans, prepro-EGF gene consists of 24 exons and encodes a 1207-residue precursor containing 9 EGF-like domains in its extracellular portion. The domain closest to the plasma membrane is released as a mature 53-aminoacid EGF, whereas the fate of additional 8 domains is unknown. EGF is detected in blood at a picomolar range, most of it being associated with platelets.
The second EGFR ligand, TGF-α, was isolated from culture media of retrovirally transformed fibroblasts as a "sarcoma growth factor" (14) , but is also synthesized in normal tissues such as decidua, brain, keratinocytes, kidneys and macrophages. HB-EGF was identified in conditioned medium of human macrophages as a mitogenic growth factor with high affinity to heparin. A characteristic feature of mature HB-EGF is its heparin-binding domain localized N-terminally to the EGF-like domain. Interaction of this domain with cell surface heparan sulfate facilitates binding of HB-EGF with its receptors. Apart from being a precursor of mature growth factor, membrane-bound proHB-EGF is a receptor for diphtheria toxin (DT) and mediates its entry to the cells. DT binds to aminoacids 106-149 within the EGF-like domain, and therefore cannot bind to truncated HB-EGF which remains in the membrane after cleavage of soluble growth factor. CRM197 is a nontoxic DT analogue with a point mutation in the catalytic domain. CRM197 binds to both membrane-bound and soluble HB-EGF and blocks its interaction with target receptors. Therefore, CRM197 is used in experimental studies to block both paracrine/autocrine and juxtacrine HB-EGF signaling. CRM197 is specific for HB-EGF and does not bind to other ErbB ligands. HB-EGF is widely expressed in various tissues including vascular endothelial and smooth muscle cells (15) (16) (17) .
Other ligands of ErbB receptors have more restricted tissue distribution and their role is less recognized. Amphiregulin (AR) was identified as an EGFR ligand produced by breast adenocarcinoma cell line; its name derives from the observations that AR may either stimulate or inhibit cell proliferation (reviewed in 18). Betacellulin (BTC) was isolated from culture media of pancreatic β-cell tumor line, however, is expressed also in normal tissues including pancreas, liver, kidney, small intestine, vascular smooth muscle and endothelial cells (for review, see ref. 19 ). Epiregulin (EPR) was purified from conditioned media of the mouse fibroblast-derived tumor cell line, but is also synthesized by vascular smooth muscle cells (20) . Neuregulins (NRG) or heregulins (HRG) create a family of four peptides encoded by separate genes with diverse tissue distribution and regulatory roles (reviewed in 21, 22).
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Soluble ErbB receptor ligands are cleaved from their membrane-bound precursors by either soluble matrix metalloproteases (MMPs) or membrane-bound metalloproteases belonging to "A Disintegrin And Metalloprotease" (ADAM) family. The identity of cleaving enzymes was identified established only in some experimental systems and, probably, each ligand precursor may be cleaved by more than one protease depending on the cell type and stimulus. However, it is generally appreciated that ADAMs are most important sheddases. ADAMs are transmembrane proteins consisting of
transmembrane domain, and (viii) cytoplasmic domain. The first recognized ADAMs (ADAM1 and ADAM2) were two subunits of a heterodimeric sperm protein, fertillin. Subsequently identified ADAMs are being numbered in an order in which they are discovered. Currently (December 2007), 40 ADAMs are known (the complete list is available online at http://people.virginia.edu/~jw7g/Table_of_the_ADAMs. html). However, only half of ADAMs bear the MP catalytic consensus motif, and catalytic activity was confirmed only for some of them. Gene knockout experiments revealed that tumor necrosis factor-α converting enzyme (TACE or ADAM17) plays an important role in the cleavage of ErbB receptor ligand precursors; other enzymes implicated in this process are ADAM9, ADAM10 and ADAM12 (23) .
TRANSACTIVATION OF EGFR BY VASOACTIVE MEDIATORS
In 1996 Daub et al (24) observed that several agonists of G-protein coupled receptors (GPCR) such as endothelin-1, lysophosphatidic acid and thrombin, rapidly activated EGFR and ErbB2 in Rat-1 fibroblasts. The phenomenon was too rapid to be mediated by stimulation of ligand synthesis de novo, and therefore was named "transactivation", i.e. ligand-independent activation. The term "transactivation" is now commonly used to describe activation of EGFR by factors other than peptide ligands listed in Table 1 , although it is evident that in most cases this phenomenon is in fact ligand-mediated. The most common mechanism of EGFR transactivation was first characterized in 1999, when Prenzel et al (25) observed that many GPCR ligands activate EGFR by stimulating HB-EGF cleavage from its membrane precursor; the mechanism referred to as "triple membrane spanning signaling" (Fig. 2) .
Several other mechanisms of EGFR transactivation have been described. Non-receptor tyrosine kinase, c-Src, phosphorylates EGFR at Tyr 845 within its TK domain and stimulates receptor kinase activity (26) . Moreover, growth hormone and prolactin activate EGFR by inducing its phosphorylation at Tyr 1068 by JAK2. Because this residue is a Grb2-docking site, JAK2 may trigger downstream ERK signaling even by mutant EGFR devoid of its TK activity (27) . A nonreceptor Ca
2+
-dependent tyrosine kinase, proline-rich tyrosine kinase (Pyk2) belonging to the focal adhesion kinase (FAK) family, has also been implicated in EGFR activation. Reactive oxygen species (ROS) may activate EGFR through multiple mechanisms. First, ROS inactivate protein tyrosine phosphatases and thus enhance EGFR activity by inhibiting its dephosphorylation. Second, ROS activate intermediate kinases which subsequently phosphorylate EGFR, such as c-Src or JAK-2. Third, ROS activate ADAMs and MMPs and stimulate ligand shedding (28) . The relationship between various EGFR-transactivation pathways is complex and cell-specific. In addition, many of these pathways such as c-Src, JAK2 and ROS may also be activated by EGFR.
The interest in role of EGFR in cardiovascular system has emerged when it was realized that this receptor is transactivated in the vascular wall and myocardium by vasoactive mediators such as angiotensin II, endothelin-1 or catecholamines -which not only induce vasoconstriction but also stimulate vascular and myocardial hypertrophy. Below are briefly characterized mechanisms of EGFR transactivation by mediators most relevant for cardiovascular (patho)physiology.
Angiotensin II
Angiotensin II (AII) -the major executor of the renin-angiotensin-aldosterone system -is one of the principal mediators regulating vascular tone and vascular smooth muscle cell hypertrophy and proliferation. Most effects of AII are mediated by AT 1 receptor, a serpentine receptor coupled to G q protein which stimulates phospholipase C to produce DAG and IP 3 from membrane phosphoinositides. DAG/PKC and IP 3 /Ca 2+ pathways mediate fast contraction of vascular smooth muscle cells in response to angiotensin II. However, AII also activates many other signaling pathways including ERKs, which play an important role in hypertrophic effect of the peptide. Currently available evidence suggest that EGFR is a central link between AT 1 receptors and many protein kinases such as ERK, c-jun N-terminal kinase (JNK), p38 MAPK, c-Src, etc.
Various mechanisms of EGFR activation by angiotensin II have been described in the cardiovascular system depending on cell type and experimental conditions (Table 3) . It should be noted that most studies were performed on isolated or cultured cells. Thus, the relevance of these findings to a complex structure of vascular wall is not clear. Moreover, some EGF receptor and hypertension CM -calmodulin, PKC -protein kinase C, NHE -sodium/proton exchanger, NOX -NADPH oxidase, CMKII -calmodulindependent protein kinase II, p70 S6K -ribosomal p70 S6 kinase, cPLA 2 -cytosolic phospholipase A 2 , PLD 2 -phospholipase D 2 , PA -phosphatidic acid, Angpt2 -angiopoietin 2, VEGF -vascular endothelial growth factor, FAK -focal adhesion kinase. "+" -increase in EGFR phosphorylation upon AII treatment was demonstrated, if specific Tyr residues which are phosphorylated were identified, they are presented in parentheses, "?" -EGFR phosphorylation was not examined, and conclusion about receptor activation is based solely on the sensitivity of response to EGFR inhibitors -sensitive nonreceptor tyrosine kinase, Pyk2 (34) . The identity of MMP/ADAMs involved in HB-EGF shedding has been established definitely only in one study (42) . It should be noted that although sensitivity of biological outcome to EGFR inhibitors (usually AG1478) was demonstrated in many cases, phosphorylation of this receptor was directly examined only in some studies and if was examined, the identity of Tyr residue(s) which are phosphorylated has not always been established.
Seshiah et al (38) described the interesting feed-forward mechanism of the prooxidant effect of AII in smooth muscle cells. It was demonstrated that AII induces a biphasic ROS formation. The early phase (minutes) results from PKC-mediated stimulation of vascular NADPH oxidase (NOX). Then, NOX-derived ROS stimulate c-Src, which phosphorylates EGFR leading to downstream activation of PI3-K. The late phase (hours) of AII-induced ROS formation results from EGFR and PI3-K-mediated NOX activation (38 (55) .
High concentration of glucose (27.5 mM) augments AII-induced EGFR transactivation in vascular smooth muscle cells. In contrast, glucose has no effect on EGF-induced EGFR phosphorylation. This effect of glucose is associated with enhanced N-glycosylation of EGFR. It has been demonstrated that 145 kD form of EGFR (predominant under normoglycemic conditions) can be activated by EGF but not transactivated by AII, whereas heavily glycosylated 170 kD EGFR is efficiently stimulated by various agonists of G-protein coupled receptors such as AII, thrombin and sphingosine 1-phosphate (56) . These data indicate that diabetes mellitus may augment transactivation of EGFR by AII, and this mechanism probably contributes to abnormalities of vascular tone (see below) and enhanced smooth muscle cell hypertrophy/proliferation in hyperglycemic states.
Although most effects of angiotensin II are mediated by AT 1 receptors, stimulation of less abundant AT 2 receptors opposes some of them. Indeed, AT 2 receptors inhibit vascular smooth muscle cell growth/proliferation and induce vasodilation (57) . Stimulation of AT 2 R opposes AT 1 R-induced EGFR phosphorylation in vascular smooth muscle cells, and this effect is mediated by stimulation of tyrosine phosphatase SHP-1 which dephosphorylates EGFR (47, 58) .
Stimulation of AT 1 receptors results in their movement to caveolae, which are microdomains of plasma membrane rich in cholesterol and sphingolipids and also contain caveolin-1. A significant fraction of unstimulated EGFR is localized in caveolae under resting conditions (59) . Within caveolae, AT 1 interacts with EGFR leading to their phosphorylation by c-Src which is also concentrated therein. In addition, c-Src phosphorylates caveolin-1 thus decreasing its affinity to EGFR. Consequently, AII induces rapid movement of phosphorylated EGFR out of caveolae and its concentration in focal adhesions, where it interacts with vinculin and paxillin. Both depletion of membrane cholesterol (which disrupts caveolae) and disruption of focal adhesions by actin-depolymerizing agents such as cytochalazin D, inhibit AII-induced EGFR transactivation in vascular smooth muscle cells (59) . Thus, caveolae and focal adhesions are specialized membrane microdomains which play an important role in AII-induced EGFR transactivation. It is postulated that binding of angiotensin II to AT 1 receptors triggers the following sequence of events (i) movement of AT 1 to caveolae, (ii) ROS formation and stimulation of c-Src, (iii) phosphorylation of EGFR and caveolin-1 by c-Src, and EGF receptor and hypertension 
Catecholamines
Two studies reported transactivation of EGFR by catecholamines in the vascular wall. Phenylephrine stimulates EGFR phosphorylation, ERK activity, and protein synthesis in isolated balloon-injured rat thoracic aorta (61) . This effect is abolished by AG1478, CRM197, anti-HB-EGF neutralizing antibody, MMP inhibitors and HB-EGF gene knockout, suggesting that phenylephrine stimulates MMP-dependent proHB-EGF shedding. In addition, Hao et al. (62) have demonstrated that phenylephrine stimulates EGFR phosphorylation at Tyr 1173 in rat mesenteric arteries in AG1478-sensitive manner.
Endothelin-1
Endothelin-1 (ET-1) is a potent vasoconstrictor, growth factor and vascular cell mitogen. In smooth muscle cells isolated from rat thoracic aorta, ET-1-induced DNA synthesis was dose-dependently inhibited by AG1478 (63) . ET-1 stimulated EGFR phosphorylation, its association with Grb2, and ERK phosphorylation in these cells, which was abolished by AG1478 (64) . The precise mechanism of ET-1-induced EGFR activation was not established, however, it was demonstrated that ET A receptor and increase in intracellular Ca 2+ were involved (64 
Aldosterone
Recent studies indicate that aldosterone does not only regulate renal Na + handling, but has also many direct effects in the cardiovascular system, including stimulation of ROS formation and inducing myocardial fibrosis (69) . Some of injurious effects of aldosterone are mediated by EGFR. Aldosterone exerts two effects on EGFR (i) increases receptor density by stimulating its gene expression in mineralocorticoid receptor (MR)-dependent manner, and (ii) transactivates EGFR by rapid non-genomic mechanism (70) . Stimulation of EGFR expression by aldosterone was first described in Chinese hamster ovary cells (71) . Recently, Grossman et al (72) have demonstrated that aldosterone infused by osmotic minipumps increases EGFR expression in aorta and myocardium of adrenalectomized rats, but has no effect on receptor level in adipose tissue and liver. The similar effect of aldosterone was observed in vitro in human aortic smooth muscle cells.
Mazak et al (73) have demonstrated that aldosterone rapidly augments angiotensin II-induced EGFR transactivation in rat aortic smooth muscle cells, and this effect is abolished by spironolactone, superoxide scavenger, tiron, and reduced glutathione. Similarly, aldosterone augmented mitogenic effect of angiotensin II on rat aortic SMCs by increasing EGFR phosphorylation level (74) . In rat aortic endothelial cells, aldosterone increases angiotensin converting enzyme (ACE) expression, the effect partially attenuated by AG1478 (75) . The mechanism through which aldosterone transactivates EGF receptor is unclear, but may include ROS, c-Src and MMPdependent shedding of EGFR ligand(s).
EGFR AND VASCULAR TONE
Many signaling pathways triggered by EGF receptor, such as IP 3 -induced increase in intracellular Ca 2+ and PKC are wellknown stimulators of vascular smooth muscle cell contraction. Moreover, ERK and PI3-K have also been implicated in vasoconstrictor response. However, the effect of EGF itself on vascular tone is controversial. Sumi et al (76) demonstrated that intravenously administered human EGF reduced blood pressure by about 8% in anesthetized dog. Consistently with this, EGF infused intraarterially potently relaxed femoral, mesenteric, coronary, carotid and renal vascular beds in this species (77) . Similarly, in conscious monkeys BP was decreased by 14-27% following EGF infusion (78) . In contrast, human EGF fragment (aminoacids 1-48) infused intravenously tended to increase BP in conscious rat
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(although the effect did not reach the level of significance) (78) . On the other hand, Gan et al (79) observed no effect of EGF administered at a very high dose (30 mg/kg) on regional hemodynamics in anesthetized rat. Taken together, the results of in vivo studies are inconsistent and suggest that EGF has a weak and possibly species-and vascular bed-specific effect on vascular tone.
In vitro, EGF constricted rat aortic rings at nanomolar concentrations with maximal constriction approaching 40% of the effect of angiotensin II (80) . Moreover, EGF augmented vasoconstrictor effect of angiotensin II on isolated rat pulmonary artery (81) . Similarly, EGF itself constricted rabbit aortic rings (82) and augmented constricting effect of bradykinin B1 receptor agonist (83) . In contrast, Namiki and Akatsuka (84) observed that EGF dilated isolated rat aortic rings preconstricted with prostaglandin F 2 or norepinephrine. This effect was endothelium-dependent and was abolished by soluble guanylate cyclase inhibitor, suggesting the involvement of endothelium-derived nitric oxide. Similarly, EGF impaired constrictor response of dog coronary artery strips to norepinephrine, although had no effect on vascular tone per se (77) .
These inconsistent results do not exclude an important role of EGFR signaling in the regulation of vascular tone for several reasons. First, exogenous EGF or other EGFR ligands are rapidly metabolized and may have limited access to their receptors. Second, EGF may have various effects on different vascular beds resulting in little or no net hemodynamic changes. Finally, EGFR "transactivated" by vasoactive mediators may play a more important role than stimulation of this receptor by its cognate ligands.
Despite many studies reporting transactivation of EGFR by vasoactive mediators (see above), only few of them addressed the role of this receptor in the regulation of vascular tone. Hao et al (62) have demonstrated that phenylephrine induces sharp and long-lasting contraction of isolated rat mesenteric artery, and that two structurally unrelated EGFR inhibitors, AG1478 and PD153035, abolished the late phase of phenylephrine-induced vasoconstriction. In contrast, these inhibitors had no effect on either basal vascular tone or on KCl-induced vasoconstriction. The effect of EGFR inhibitors was mimicked by ERK but not by p38 MAPK or PI3-K inhibitors, suggesting the major role of ERK in vasoconstriction. In addition, vasoconstriction induced by α 1 -adrenergic agonists was abolished by CRM197 and anti HB-EGF antibody, as well as by MMP inhibitor, GM6001 (62) . Subsequently, the same group has demonstrated that EGFR transactivated by phenylephrine increases ROS formation specifically in mitochondria, which is accompanied by hyperpolarization of internal mitochondrial membrane, suggesting enhanced mitochondrial oxidation. Combined pharmacological and genetic approaches have revealed that inhibiting mitochondrial ROS formation attenuates vascular effect of phenylephrine (85) . The mechanism through which EGFR stimulates mitochondrial ROS formation, and how mitochondrial ROS increase vascular tone, remains to be established. Flamant et al (67) have demonstrated that ET-1-induced contraction of mice aortic rings is abolished by EGFR inhibitor, PD153035. In addition, increase in blood pressure induced by bolus intravenous ET-1 in anesthetized mice is reduced by pretreatment with either PD153035 or AG1478, whereas neither of these inhibitors has any effect on BP in animals not receiving ET-1 (67) . Moreover, ET-1-induced increase in blood pressure is markedly impaired in waved-2 mice, which bear spontaneous mutation in the egfr gene. Similarly, BP-elevating effect of ET-1 is attenuated in HB-EGF -/-mice (86) . In vitro, ET-1 induced contraction of isolated carotid artery segments is attenuated in waved-2 mice and in HB-EGF -/-mice, whereas these genotypes have no effect on KCl-induced contraction (86) . It has been demonstrated that these mutations, as well as pharmacological blockade of EGFR, PI3-K, HB-EGF or MMP in wild-type mice reduced ET-1-induced Ca 2+ influx to mice and human vascular smooth muscle cells (86) . Moreover, AG1478 inhibited ET-1-induced EGFR phosphorylation and contraction of rabbit basilar artery rings in a dose-dependent manner both in vitro and in vivo (87). Carmines et al (88) have demonstrated that AII-induced constriction of isolated rat renal afferent and efferent arterioles was abolished by AG1478 but not by EGFR-inactive analogue, AG9. In contrast, Escano et al have recently demonstrated that AII stimulates ERK in SMCs isolated from rat renal microvessels in EGFR-independent but Src-dependent manner, whereas stimulation of ERK in SMCs isolated from thoracic aorta is EGFR-dependent (89) . These data suggest that EGFR is involved in vascular effect of angiotensin II only in large conduit vessels which are not involved in the regulation of peripheral resistance and blood pressure. Consistently with this, AG1478 had no acute effect on blood pressure either in control or in angiotensin II-infused rats (40, 89) . Finally, Lucchesi et al. (90) have demonstrated that MMP2 and/or MMP9-mediated HB-EGF shedding and EGFR transactivation contribute to the development of myogenic tone (vasoconstriction induced EGF receptor and hypertension by increased perfusion pressure) in mouse mesenteric artery. Taken together, these data suggest that EGFR mediates vasoconstriction in response to various humoral and mechanical factors, at least in some vascular beds.
EGFR AND RENAL SODIUM HANDLING
EGF is synthesized in the medullary thick ascending limb of the loop of Henle (mTAL) and in distal convoluted tubule (DCT) of various mammalian species (91, 92) . ProEGF is detected in the apical membrane of tubular cells, and mature EGF is cleaved to the tubular fluid and is excreted in urine at relatively high levels (10 -7 -10 -8 M versus 10 -11
M in plasma). Removal of salivary glands, a major source of plasma EGF (12) , has no effect on EGF excretion in urine, suggesting that the kidney is a predominant source of urinary peptide (93) . Interestingly, EGF receptors are localized in the basolateral membranes of tubular cells making it unlikely that locally generated EGF binds to these receptors. However, other EGFR ligands such as TGFα and HB-EGF are also abundantly expressed in the kidney. TGFα is synthesized in medullary and, to a lesser extent, in cortical collecting ducts (94) . The highest density of EGF receptors is detected in proximal straight tubule (PST), followed by proximal convoluted tubule (PCT), cortical collecting duct (CCD), inner medullary collecting duct (IMCD), outer medullary collecting duct (OMCD) and distal convoluted tubule (95) . It should be noted that EGF receptors are expressed only at low level in DCT and are not expressed at all in mTAL, two major sites of intrarenal EGF production.
EGF is a potent mitogen for renal tubular and mesangial cells and, therefore, renal EGFR signaling has been studied mainly in the context of hyperproliferative kidney diseases such as diabetic nephropathy. EGFR plays an important role in renal regeneration after acute toxic or ischemic insults. In addition, abnormal EGFR sorting to the apical membranes of tubular cells may contribute to the development of polycystic kidney diseases. Much less is known about the role of EGF and its receptor in the regulation of renal sodium handling. The results of in vivo studies examining the effect of EGF on renal function are controversial. Infusion of EGF to the renal artery of anesthetized rat induces reversible decrease in glomerular filtration rate (GFR) due to constriction of pre-and postglomerular vessels (reduced renal blood flow), and mesangial cell contraction (decrease in filtration fraction). These effects result in the decrease in sodium and potassium excretion, however, urine volume does not change, which suggests increased free water clearance (96) . In contrast, infusion of betacellulin by osmotic minipumps for 7 days increased urine output by almost 100% in the rat (97 (115) . Despite various experimental protocols, these two studies (114, 115) suggest that EGF and possibly other intrarenally generated EGFR ligands stimulate sodium pump in tubular cells.
TRANSACTIVATION OF EGF RECEPTOR IN TUBULAR CELLS AND ITS ROLE IN ROS-DEPENDENT ALTERATIONS OF NA + TRANSPORT
Renal Na + reabsorption is stimulated by mediators which reduce natriuresis and increase blood pressure such as norepinephrine and angiotensin II, and inhibited by natriuretic factors such as dopamine, nitric oxide and atrial natriuretic peptide (112) . Little is known about the effect of these mediators on EGFR phosphorylation level in tubular cells. However, angiotensin II transactivates EGF receptor in rabbit and mouse proximal tubular cells (116) (117) (118) It is possible that a part of antinatriuretic effect of mediators such as angiotensin II, norepinephrine and endothelin-1 is mediated by EGFR. In addition, ROS stimulate tubular Na + transport and therefore, enhanced intrarenal oxidative stress may contribute to the development of arterial hypertension (128) . This antinatriuretic effect of ROS is usually attributed to scavenging of nitric oxide, which is generated in the kidney in relatively high amounts and exerts a tonic inhibitory effect on Na + transport (129) . However, ROS may stimulate Na + reabsorption also in NO-independent manner (130) . Indeed, hydrogen peroxide stimulates Na + transport in amphibian A6 tubular cell monolayers by activating EGFR (131) . Taking into account these observations, we examined the effect of H 2 O 2 infused to the renal artery under general anesthesia on renal Na + ,K + -ATPase activity in the rat. We observed that H 2 O 2 increased renal cortical and medullary Na + ,K + -ATPase activity and this effect was abolished by ERK inhibitor, PD98059 (132) . Previously, it has been shown that H 2 O 2 infused into the renal medullary interstitium reduces natriuresis and increases blood pressure in the long run (133, 134) . Thus, renal Na + ,K + -ATPase may mediate antinatriuretic and blood pressure-elevating effect of H 2 O 2 . These findings may explain a "H 2 O 2 paradox", i.e. the contradictive observations that plasma H 2 O 2 level is increased in hypertensive animals and humans and that blood pressure is reduced in catalaseoverexpressing mice (which suggests prohypertensive effect of H 2 O 2 ), despite the fact that H 2 O 2 dilates blood vessels and may operate as an endothelium-dependent hyperpolarizing factor (132) . Subsequently, we have demonstrated that H 2 O 2 increases c-Src phosphorylation level at Tyr 418 , ERK 1/2 phosphorylation, and EGFR phosphorylation at Tyr 845 and, to a lesser extent, at Tyr 1068 in the renal cortex and medulla (135, 136) . The effect of H 2 O 2 on c-Src phosphorylation was abolished by Src kinase inhibitor, PP2, but not by AG1478 or PD98059, its effect on EGFR phosphorylation was abolished by PP2 and AG1478, and effect on ERK phosphorylation EGF receptor and hypertension and Na + ,K + -ATPase activity by both these inhibitors as well as by PD98059. These data indicate that H 2 O 2 stimulates renal sodium pump by the mechanism involving sequential activation of c-Src, EGF receptor and ERK (115) . Moreover, GM6001, CRM197 and anti-HB-EGF neutralizing antibody had no effect on H 2 O 2 -induced Src-EGFR-ERK pathway at doses at which these inhibitors partially attenuated the effect of angiotensin II, suggesting that metalloprotease-dependent shedding of HB-EGF precursor plays only minor role in the stimulation of renal EGFR by H 2 O 2 . These results indicate that EGFR and ERK-dependent stimulation of Na In addition, the level of mRNA EGFR is permanently higher in SHR than in WKY rats (138). Hao et al (62) observed that activity of MMP-7 was enhanced in mesenteric arteries of SHR, which was accompanied by accelerated HB-EGF processing. Interestingly, this was observed at the onset of hypertension (at the age of 5 weeks), suggesting that HB-EGF/EGFR signaling contributes to the development of hypertension rather than is secondary to blood pressure elevation. Moreover, the effect of angiotensin II on EGFR and ERK phosphorylation was enhanced in aortic smooth muscle cells isolated from SHR (139) . Consistently with these observations, EGF constricted endothelium-denuded thoracic aorta isolated from SHR but not from WKY (140). Swaminathan and Sambhi (141) observed a 3-fold higher density of EGF receptors in the kidney and 2-fold higher receptor density in aorta of Dahl salt-sensitive rats kept on high salt diet in comparison to Dahl salt-resistant animals. Moreover, affinity of EGFR to its ligand was greater in aorta (but not in the kidney) of salt-sensitive rats kept on high-salt diet. EGFR mRNA and protein levels are greater in the renal cortex of DSSR than in salt-resistant rats even before the development of hypertension, suggesting that enhanced EGFR signaling is not secondary to blood pressure elevation. Interestingly, high-salt diet had no effect on EGF receptor abundance in the kidney of normotensive Sprague-Dawley rats, but further increased receptor density in the kidney of Dahl salt-sensitive rats (142 (142) . Finally, increased EGF receptor density was observed in the kidney and aorta of Lyon hypertensive rats compared to Lyon normotensive rats (143) . Controversies exist as to whether EGFR signaling is altered in stroke-prone SHR (SHRSP), a substrain of SHR especially prone to develop ischemic cerebral stroke. Kim et al (144) observed no difference in EGFR expression and phosphorylation level in aorta between SHRSP and control WKY rats. In addition, EGFR phosphorylation in SHRSP was similar before (5 week-old animals) and after (10-20 week-old animals) the development of hypertension. In contrast, Dorrance et al (145) found increased proEGF and EGFR mRNA levels in aorta and cerebral arteries of adult SHRSP. In addition, EGFR mRNA (but not mRNA proEGF ) level was higher in young prehypertensive animals.
Controversies also exist about role of EGFR in angiotensin II-induced hypertension. Kim et al (50) observed that although acute infusion of angiotensin II increased EGFR phosphorylation level in the rat aorta, AII infusion for 3 days had no effect on EGFR phosphorylation but stimulated phosphorylation of platelet-derived growth factor receptor. In the other study, hypertension induced in the rat by 4-week infusion of AII was associated with increased mRNA EGFR and protein level in aorta, but phosphorylation of the receptor was not examined (146). Lautrette et al (147) studied the role of renal EGFR in the development of angiotensin II-induced hypertension and renal damage. It was demonstrated that infusion of angiotensin II for 2 months increased blood pressure by about 40 mmHg in mice, which was associated with higher renal TGFα protein (but not mRNA) level, greater ADAM17/TACE activity, and enhanced EGFR phosphorylation (but not absolute EGFR level) in the kidney. However, expression of a dominant-nega-
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tive EGFR specifically in the proximal tubule, TGFα gene knockout, or treatment with ADAM17/TACE inhibitor did not reduce BP in this model, although these treatments normalized EGFR phosphorylation and prevented renal damage. Although these data suggest that renal EGFR is not involved in AII-induced hypertension, it should be noted that neither of these approaches completely eliminated EGFR signaling. Dominant-negative EGFR was expressed only in the proximal tubules, TGFα -/-genotype did not eliminate other EGFR ligands, and TACE inhibitor did not block ligand processing by other MMP/ADAMs. Thus, although AII is a well-established EGFR transactivator (Table 3) , role of EGFR in AII-induced hypertension is, paradoxically, controversial. Several studies examined the role of EGFR in arterial hypertension induced by deoxycorticosterone acetate (DOCA) and high-salt diet. Florian et al (148) observed that EGF and TGF-α constricted aortic rings isolated from DOCA-salt rats but had no effect in normotensive animals. The similar vasoconstrictor effect was observed in 1-kidney 1-clip hypertension model. Constrictor response to EGF was observed after 14 days of DOCA-salt treatment when blood pressure is already elevated. These findings suggest that EGFR does not drive the development of hypertension in this model, but may contribute to the maintenance of high blood pressure. Increased vasoconstrictor potency of EGF results most likely from excess of mineralocorticoids rather than from blood pressure elevation, since DOCA-salt treatment induces a similar phenomenon in Wistar-Furth rats in which blood pressure only marginally increases. Although EGFR mRNA level is increased in aorta of DOCA-salt rats, the level of receptor itself is unchanged, suggesting that enhanced constricting effect of EGF is a postreceptor phenomenon (149) . Enhanced constrictor response to EGF in DOCA-salt rats is mediated by ERK, PI3-K, and partially by PKC and Rho-dependent kinase (150) .
Chronic administration of synthetic nitric oxide synthase inhibitors such as Nω-nitro-L-arginine (L-NNA) or Nω-nitro-L-arginine methyl ester (L-NAME) is an established model of hypertension. It has been shown that EGF contracts thoracic aorta of L-NNA-treated hypertensive rats to the greater extent than aorta of control animals (140) .
EGFR IN LEPTIN-INDUCED AND OBESITY-ASSOCIATED HYPERTENSION
Metabolic syndrome (MS) is a commonly observed cluster of related abnormalities which directly or indirectly result from central obesity. The most important components of MS are insulin resistance, hyperinsulinemia, dyslipidemia (reduced HDL and increased triglycerides), elevated blood pressure, and impaired glucose tolerance or overt type 2 diabetes. Metabolic syndrome is a major cause of arterial hypertension. Indeed, it is estimated that in developed countries about 2/3 cases of arterial hypertension are directly associated with excess body weight (151) .
Little is known about role of EGFR in arterial hypertension associated with the MS. Several studies have demonstrated increased EGFR phosphorylation level in mesenteric (152) , coronary (153) and renal arteries (154) of rats with experimental streptozotocin-induced diabetes. In addition, AG1478 corrects abnormal vascular reactivity (e.g. reduces enhanced reactivity to vasoconstrictors and improves impaired reactivity to vasodilators) in diabetic but not in control animals. However, streptozotocin-induced diabetes is a model of type 1 diabetes, which is not a component of MS and is not associated with hypertension until nephropathy develops. Recently, increase in absolute and phosphorylated EGFR levels was observed in the kidney of Goto-Kakizaki rats, a model of type 2 diabetes and hypertension (155) . However, this model is characterized by lower body weight, hypoinsulinemia and hypotriglyceridemia, and thus does not reproduce abnormalities associated with the MS.
Although the mechanism of MS-related hypertension is incompletely understood, recent studies suggest an important role of adipose tissue-derived signaling proteins designated adipokines (156) . In particular, leptin, a product of the ob gene, is secreted by adipose tissue and regulates energy balance by inhibiting food intake and stimulating energy expenditure. Several lines of evidence suggest the role of leptin in obesity-associated hypertension (i) plasma leptin concentration is increased in obese subjects reflecting greater amount of adipose tissue and resistance to anorectic effect of this hormone, (ii) chronic leptin administration or transgenic overexpression increase BP in experimental animals, and (iii) high leptin correlates with increased BP in humans independently of body weight (157) (158) (159) . Previously, we and others have examined the model of hypertension induced in healthy rats by central or peripheral administration of exogenous leptin. Although this model does not reproduce all abnormalities associated with obesity, it allows studying specific consequences of leptin excess (158, 160) . Although the role of EGFR in this model, as well as in other models of obesity-associated hypertension, was not previously investigated, some observations suggest that leptin may be associated with EGFR signaling. First, it was EGF receptor and hypertension observed 20 years ago that EGFR expression in the liver was reduced in three models of obesity associated with deficient leptin signaling, leptin-deficient ob/ob mice, leptin resistant db/db mice, and leptin resistant Zucker fa/fa rat (161) . Second, EGF and other EGFR ligands such as HB-EGF are produced in adipocytes and stimulate adipogenesis, which suggests that their production may be enhanced in obesity (162) . Indeed, plasma HB-EGF positively correlates with body mass index (163) . Third, unsaturated fatty acids, which circulate in increased amounts in obese subjects, activate EGFR through the unknown mechanism (164) . Finally, leptin has been shown to transactivate the EGF receptor in several cancer cell lines (165, 166 and PD158780, as well as by Src inhibitor, PP2. Moreover, the effect of leptin was unaffected by GM6001. Taken together, these data suggest that leptin stimulates renal sodium pump by transactivating the EGF receptor in H 2 O 2 and c-Src dependent but MMP-independent manner (115) .
Likewise, we have recently demonstrated that experimental hyperleptinemia induced in normal rats by 7-day administration of exogenous hormone induces blood pressure elevation and impairs Na + excretion by stimulating renal Na + ,K + -ATPase (160, 168) . Moreover, these effects were prevented by NOX inhibitor, apocynin, suggesting the involvement of oxidative stress (169, 170) . Therefore, in subsequent studies we aimed to elucidate if EGFR-ERK pathway is activated when leptin is administered systemically for prolonged period of time and, if so, whether this pathway contributes to BP elevation in our hyperleptinemic model.
We demonstrated that leptin infused into the abdominal aorta increases EGFR phosphorylation level at Tyr 845 and, to a lesser extent, Tyr 1068 , not only in the kidney but also in the aortic wall (135) . Moreover, leptin stimulated c-Src and ERK1/2 phosphorylation in the aortic wall. Although aorta is a large conduit artery and does not contribute to the regulation of vascular tone, these data suggest that leptin transactivates EGFR also in the vascular wall. In addition, we observed that if leptin is administered systemically at a dose of 0.5 mg/kg/ day which raises its plasma concentration about fourfold, ERKs are transiently stimulated, i.e. ERK1/2 phosphorylation level in the kidney and aortic wall is markedly elevated after 4 days but only moderately elevated after 8 days of leptin administration (136) . Moreover, ERK inhibitor, PD98059, reduced BP in the early phase (3-5 days) but not in the later phase (6-8 days) of leptin administration (136 (10) . Until now, very little is known about effect of these drugs on blood pressure in humans.
Studies in which attempts have been undertaken to inhibit EGFR in experimental hypertension are listed in Table 4 . These attempts may be divided into two groups. The first group includes "specific" therapies such as EGFR kinase inhibitors, as well as inhibitors of transactivation pathways (e.g. Src or MMP/ADAM inhibitors). As can be seen, the effect of these treatments on BP is controversial. EGFR-specific antisense oligodeoxynucleotides were used in two studies but only partially reduced blood pressure (173, 174) . However, antisense oligonucleotides only partially reduced total EGFR expression, and thus could not completely block its activity. EGFR kinase inhibitors were tested in two studies; AG1478 normalized blood pressure in leptin-induced hypertension (136), whereas gefitinib had no effect on BP in L-NAME induced hypertension (175) . It should be noted that blood pressure is much higher in the L-NAME model (mean BP about 170 mmHg) than in our study (SBP about 150 mmHg), and L-NAME was administered for 4 weeks (175) vs. 1-week leptin treatment in our study. It is possible that EGFR blockade is more effective in reducing BP in moderate than in severe hypertension. Among MMP/ADAM inhibitors, doxycycline reduced BP in SHR (62), but two more selective inhibitors had no effect on BP in angiotensin II-induced or phenylephrine-induced hypertension (31, 147) . It should be noted that doxycycline is a broad-range MMP/ADAM inhibitor, whereas compounds used in the remaining studies were selective toward specific ADAMs and therefore could be less effective.
Despite these inconsistencies, EGFR is potentially a very attractive target for antihypertensive therapy. First, EGFR is a "final common pathway" for various vasoconstrictors and thus its inhibition may be more effective than specific therapies aimed to block only one of these mediators. Second, inhibiting EGFR may reduce target organ damage such as glomerulopathy or left ventricular hypertrophy even independently of lowering BP. Third, some vessel-dilating hypotensive drugs such as Ca 2+ antagonists or α 1 -adrenergic receptor antagonists may impair renal perfusion and induce fluid retention. If EGFR mediates enhanced tubular Na + reabsorption as suggested by some studies, inhibiting it may simultaneously normalize vascular tone and renal Na + handling. Finally, hyperleptinemia, which accompanies the MS, may contribute to the development of malignancies (176, 177) , possibly via transactivating the EGFR (165,166) ; thus, inhibiting EGFR could simultaneously reduce the risk of cancer in hyperleptinemic states. EGFR signaling is also affected by less specific antihypertensive therapies such as RAAS inhibitors, ET-1 receptor antagonists and antioxidants (Table 4) , some of them are well established antihypertensive drugs or are known to reduce blood pressure in experimental models. The effect of these treatments on EGFR was, however, addressed only in few studies. Angiotensin-converting enzyme inhibitor, imidapril, AT 1 receptor antagonist, losartan, and aldosterone antagonist, spironolactone, have been shown to reduce EGFR phosphorylation level in some, but not all, studies (Table 4) . However, each of these drugs has EGFR-independent effects, so the causal relationship between inhibiting EGFR and lowering BP remains unclear. ERK inhibitor, PD98059, has been consistently demonstrated to reduce BP in several models of hypertension (136, 179, 180) , but ERKs are activated by factors other than EGFR, so ERK inhibitors may be more effective than EGFR inhibitors. Finally, NOX inhibitor, apocynin, reduces blood pressure in many experimental models, but its effect on EGFR phosphorylation in vivo is controversial (136, 178) . In theory, other strategies may also be undertaken to inhibit EGFR in hypertension, such as cholesterol depletion in caveolae by drugs like statins, AT 1 receptor antagonists blocking selectively its G-protein independent interaction with EGFR, farnesyltransferase inhibitors which inhibit farnesylation of Ras proteins, or c-Abl inhibitors such as imatinib (Glyvec) currently used in the treatment of chronic myelogenous leukemia.
CONCLUSION AND PERSPECTIVES
Data presented above strongly suggest that EGFR is involved in the pathogenesis of arterial hypertension, at least in some animal models. EGFR is abundantly expressed in the vascular wall and renal tubules, and this receptor -either activated by its peptide ligand(s) or transactivated by factors such as ROS, angiotensin II or leptin -may elicit vasoconstriction and renal Na + retention. Enhanced EGFR signaling has been observed in many animal models of hypertension, and inactivation of this receptor by genetic or pharmacological approaches reduces blood pressure in some of these models. Nevertheless, many aspects remain to be clarified. It is unknown if EGFR plays any role in human hypertension. It EGF receptor and hypertension 
Leptin-induced hypertension rat PD98059   EGFR phosphorylation in aorta and kidney (136) *moderate decrease in comparison to AII-treated group, but not complete normalization ** reduction of SBP by 10% only in young but not in adult animals. ***no change in absolute level of EGFR mRNA was observed; EGFR phosphorylation was not studied
Bełtowski and Jamroz-Wiśniewska is also unclear if other ErbB receptors are transactivated by mechanisms similar to EGFR and, if so, whether these receptors are involved in the regulation of vascular tone and renal Na + transport. Currently, it is much too early to recommend EGFR inhibitors for the treatment of hypertension. The effect of these drugs on BP in humans must first be examined, possibly initially in a subset of patients with hypertension and cancers for which these drugs are currently indicated. However, even if positive response is observed, the concern of possible side effects will remain, especially if it is realized that EGFR kinase inhibitors may also target other ErbB receptors, particularly in vivo when compound concentration in all compartments cannot be strictly controlled. In this context, it should be noted that trastuzumab induces cardiomyopathy in a subset of patients (181) .
